Prospects for the use of the marker of systemic inflammation GDF-15 in cardiooncology
AbstractThe number of patients with acute coronary syndrome (ACS) and cancer is growing among the population. The tactic of management of such patients is interdisciplinary interaction of cardiology and oncology, due to the peculiarities of diagnosis, course and high level of complications. There is a problem of early and timely diagnosis of subclinical cardiotoxicity in the progression of cancer and how to predict cardiovascular complications in the near and long term. One possible solution is to use a multi-marker approach that combines necrosis markers (Tn), myocardial stress (NT-proBNP) and systemic inflammation (GDF-15, hs-CRP).
Keywords:cardiooncology, acute coronary syndrome, cancer, cardiovascular disease, ACS without ST-segment elevation, ACS with ST-segment elevation, GDF-15
For citation: Shalenkova M.A., Ivanov A.V., Klimkin P.F. Prospects for the use of the marker of systemic inflammation GDF-15 in cardiooncology. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2019; 7 (1): 51-9. doi: 10.24411/2309-1908-2019-11006. (in Russian)